# OnCo record gefitinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/gefitinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "gefitinib" ;
  schema:name "Gefitinib"@en ;
  schema:description "The lung-cancer pill whose dramatic responses in a few patients led to the discovery of EGFR mutations in 2004."@en ;
  schema:url <https://onco.cc/drugs/gefitinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Gefitinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q417824> ;
  schema:citation <https://doi.org/10.1056/NEJMoa0810699>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=gefitinib> ;
  onco:status "approved" ;
  onco:tag "gap-fill", "generic" ;
  onco:modality "Small-molecule EGFR TKI (first generation, reversible)" ;
  schema:alternateName "Iressa" ;
  onco:approval "US 2003: NSCLC after chemotherapy (accelerated; restricted 2005)", "EU 2009: EGFR-mutant NSCLC", "US 2015: First-line NSCLC with EGFR exon 19 del or L858R" ;
  onco:acceleratedApproval "US 2003-05-05: As monotherapy for locally advanced or metastatic NSCLC after failure of platinum-based and docetaxel chemotherapy" ;
  onco:related <https://onco.cc/biomarkers/egfr-exon-19-deletion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/oncogene-addiction/> ;
  onco:trials <https://onco.cc/trials/gefitinib-chemo-tmh/>, <https://onco.cc/trials/nct02411448/>, <https://onco.cc/trials/nct03944772/>, <https://onco.cc/trials/nct03040973/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/> .
